Jonathan A Meisel1, Hau D Le2, Vincent E de Meijer2, Vania Nose3, Kathleen M Gura4, Robert V Mulkern5, M Reza Akhavan Sharif6, Mark Puder2. 1. Department of Surgery and the Vascular Biology Program, Children's Hospital Boston, Boston, MA 02115, USA. Electronic address: jmeisel@bidmc.harvard.edu. 2. Department of Surgery and the Vascular Biology Program, Children's Hospital Boston, Boston, MA 02115, USA. 3. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 4. Department of Pharmacy, Children's Hospital Boston, Boston, MA 02115, USA. 5. Department of Radiology, Children's Hospital Boston, Boston, MA 02115, USA. 6. Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Abstract
BACKGROUND: Plant-based intravenous lipid emulsions have been shown to contribute to parenteral nutrition-associated liver disease (PNALD). There is mounting evidence that fish oil-based emulsions may prevent this liver injury. This study compares 5 emulsions with different fat compositions and their effect on hepatic steatosis, one of the first hits in PNALD. METHODS: C57BL/6J mice were placed on a fat-free diet and randomized into 5 equal groups. Each group received one of the commercially available intravenous lipid emulsions (Intralipid [Baxter/Fresenius Kabi, Deerfield, Ill], Liposyn II [Hospira Inc, Lake Forest, Ill], ClinOleic [Baxter/Clintec Parenteral SA, Cedex, France], SMOFlipid [Fresenius Kabi, Bad Homburg, Germany], or Omegaven [Fresenius Kabi Deutschland GmbH]) or normal saline. Liver enzymes, degree of steatosis, and fatty acid compositions were analyzed after 19 days. RESULTS: Intralipid, Liposyn II, ClinOleic, and SMOFlipid groups all demonstrated moderate steatosis with hepatic fat contents of 17.4%, 21.9%, 22.5%, and 12.6%, respectively. Omegaven mice, however, had normal livers. Saline control mice developed biochemical evidence of essential fatty acid deficiency (EFAD). Lipid supplementation with Intralipid, Liposyn II, and Omegaven prevented the onset of biochemical EFAD, whereas administration of ClinOleic and SMOFlipid did not. CONCLUSION: The fish oil-based lipid emulsion Omegaven prevented hepatic steatosis and EFAD in this murine model. ω-3 fatty acids may be efficacious in preventing PNALD and should be explored in the development of novel lipid emulsions.
BACKGROUND: Plant-based intravenous lipid emulsions have been shown to contribute to parenteral nutrition-associated liver disease (PNALD). There is mounting evidence that fish oil-based emulsions may prevent this liver injury. This study compares 5 emulsions with different fat compositions and their effect on hepatic steatosis, one of the first hits in PNALD. METHODS: C57BL/6J mice were placed on a fat-free diet and randomized into 5 equal groups. Each group received one of the commercially available intravenous lipid emulsions (Intralipid [Baxter/Fresenius Kabi, Deerfield, Ill], Liposyn II [Hospira Inc, Lake Forest, Ill], ClinOleic [Baxter/Clintec Parenteral SA, Cedex, France], SMOFlipid [Fresenius Kabi, Bad Homburg, Germany], or Omegaven [Fresenius Kabi Deutschland GmbH]) or normal saline. Liver enzymes, degree of steatosis, and fatty acid compositions were analyzed after 19 days. RESULTS:Intralipid, Liposyn II, ClinOleic, and SMOFlipid groups all demonstrated moderate steatosis with hepatic fat contents of 17.4%, 21.9%, 22.5%, and 12.6%, respectively. Omegaven mice, however, had normal livers. Saline control mice developed biochemical evidence of essential fatty acid deficiency (EFAD). Lipid supplementation with Intralipid, Liposyn II, and Omegaven prevented the onset of biochemical EFAD, whereas administration of ClinOleic and SMOFlipid did not. CONCLUSION: The fish oil-based lipid emulsion Omegaven prevented hepatic steatosis and EFAD in this murine model. ω-3 fatty acids may be efficacious in preventing PNALD and should be explored in the development of novel lipid emulsions.
Authors: Meredith A Baker; Bennet S Cho; Lorenzo Anez-Bustillos; Duy T Dao; Amy Pan; Alison A O'Loughlin; Zachary M Lans; Paul D Mitchell; Vania Nosé; Kathleen M Gura; Mark Puder; Gillian L Fell Journal: Am J Clin Nutr Date: 2019-04-01 Impact factor: 7.045
Authors: Gillian L Fell; Bennet S Cho; Duy T Dao; Lorenzo Anez-Bustillos; Meredith A Baker; Prathima Nandivada; Amy Pan; Alison A O'Loughlin; Paul D Mitchell; Vania Nose; Kathleen M Gura; Mark Puder Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2019-03-05 Impact factor: 4.006
Authors: Meredith A Baker; Paul D Mitchell; Alison A O'Loughlin; Alexis K Potemkin; Lorenzo Anez-Bustillos; Duy T Dao; Gillian L Fell; Kathleen M Gura; Mark Puder Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-06 Impact factor: 4.016
Authors: Brian T Kalish; Hau D Le; Jonathan M Fitzgerald; Samantha Wang; Kyle Seamon; Kathleen M Gura; Karsten Gronert; Mark Puder Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-10-03 Impact factor: 4.052
Authors: Hau D Le; Erica M Fallon; Brian T Kalish; Vincent E de Meijer; Jonathan A Meisel; Kathleen M Gura; Vania Nose; Amy H Pan; Bruce R Bistrian; Mark Puder Journal: Metabolism Date: 2012-11-12 Impact factor: 8.694
Authors: Orly L Levit; Kara L Calkins; L Caroline Gibson; Lorraine Kelley-Quon; Daniel T Robinson; David A Elashoff; Tristan R Grogan; Ning Li; Matthew J Bizzarro; Richard A Ehrenkranz Journal: JPEN J Parenter Enteral Nutr Date: 2014-06-24 Impact factor: 4.016